About erasca inc - ERAS
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
ERAS At a Glance
Erasca, Inc.
3115 Merryfield Row
San Diego, California 92121
| Phone | 1-858-465-6511 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -161,650,000.00 | |
| Sector | Health Technology | Employees | 103 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ERAS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.679 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.291 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.152 |
ERAS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,569,417.476 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ERAS Liquidity
| Current Ratio | 9.836 |
| Quick Ratio | 9.836 |
| Cash Ratio | 9.502 |
ERAS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -36.009 |
| Return on Equity | -43.678 |
| Return on Total Capital | -34.004 |
| Return on Invested Capital | -38.518 |
ERAS Capital Structure
| Total Debt to Total Equity | 12.252 |
| Total Debt to Total Capital | 10.915 |
| Total Debt to Total Assets | 10.326 |
| Long-Term Debt to Equity | 11.162 |
| Long-Term Debt to Total Capital | 9.943 |